113 results
10-K
2023 FY
EX-10.6
INTI
Inhibitor Therapeutics, Inc.
Annual report
29 Mar 24
4:05pm
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
18 Oct 23
Departure of Directors or Certain Officers
9:54am
8-K
EX-10.1
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.4
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.3
INTI
Inhibitor Therapeutics, Inc.
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.2
f46jq
19 Dec 22
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
lk3d dp29
18 Jan 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-10.1
8v2vuk0gw
17 Dec 20
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-10.1
pbq07tysk0gh55v
6 May 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-10.2
cpzj8k 7smuibxrkhlj0
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.1
yczgla
31 Dec 18
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-10.1
tomcdkmk 2g
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am
8-K
EX-10.2
q5yy6 3i0f
11 Jan 18
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
12:00am